期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助化疗与乳腺癌病理组织形态学及分子水平相关基因的表达 被引量：1

Neoadjuvant Chemotherapy and Pathological Histomorphology as well as Expression of Related Gene at Molecular Level in Breast Cancer
下载PDF
导出
摘要 新辅助化疗是指在实施手术或放疗之前应用的全身性化疗,对乳腺癌有良好的近期疗效,同时为化疗药体内药敏试验提供了可靠的依据。以往对新辅助化疗疗效的评定仅限于常规镜下观察化疗后病理形态学改变的组织学评定,结合肿瘤特异性标志物的检测是一种新尝试,从不同层面对新辅助化疗后乳腺癌组织的变化进行观察,客观评价新辅助化疗对指导临床个体化化疗的作用。 Neoadjuvant chemotherapy is a systemic chemotherapy before surgical operation or radiotherapy. It is good for the breast cancer with the recent response rate and it offers the credible evidence to susceptibility test of chemotherapeutic agent in vivo. The evaluation on the response rate of neoadjuvant chemotherapy is only limited to the routine method of pathological histomorphology below the microscope. It is a new essay to analyze the relationship between the tumor markers and chemotherapy reaction, in order to observe the change of breast cancer tissues in different aspects after neoadjuvant chemotherapy with better prospect of clinical individual chemotherapy.
作者 刘巍 张祥宏
机构地区 河北医科大学基础研究所病理室
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第18期1076-1080,共5页 Chinese Journal of Clinical Oncology
关键词 新辅助化疗 乳腺癌 基因 Neoadjuvant chemotherapy Breast cancer Gene
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902[J].J Clin Oncol, 2001, 19(22): 4224～4237.
  • 2Newman LA, Buzdar AU, Singletary SE, et al. A prospective trail of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility[J]. Ann Surg Oncol,2002, 9(3): 228～234.
  • 3Ezzat AA, Ibrahim EM, Ajarim DS, et al. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin[J]. Breast Cancer Res Treat, 2000, 62(3):237～244.
  • 4Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial [J]. Clin Cancer Res, 2002, 8(5): 1073～1079.
  • 5Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002, 20(6): 1456～1466.
  • 6NSABP. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27 [J]. Breast Cancer Res Treat, 2001, 69(3): 210.
  • 7Isabelle VP, Herve C, Bernard L, et al. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer[J]. The Oncologist, 2002, 7(5): 418～423.
  • 8Braud AC, Levy EM, Feuilhade F, et al. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase Ⅱ study [J]. AmJ Clin Oncol, 2002, 25(3): 303～307.
  • 9Comez H, Kahatt C, Falcon S, et al. A phase Ⅱ study of neoadjuvant gemcitabine plus doxorubicin in stage Ⅰ - Ⅱ B breast cancer: a preliminary report [J]. Semin Oncol, 2001, 28 (3 Supple): 57～61.
  • 10Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer[J]. AmJ Surg, 1998, 176(6): 502～509.

二级参考文献46

  • 1王贤才.临床药物大典[M].青岛：青岛出版社,1990.1558.
  • 2王贤才.临床药物大典[M].青岛:青岛出版社,1990.1558.
  • 3Fleteher K. Drug delivery: Strategiies and technologies [J].PSTT, 1998,1(2) : 49-52.
  • 4Tsai JY, Safram H. Status of treatment for advanced gastric carcinoma [J]. Curr Oncol Rep, 2003,5(3) :210-218.
  • 5Nagaich S, Khopade AJ, Jain NK. Lipo Grafts of egg-box.complex, a new supramdecular biovector for 5-fliuorouracil delivery [J]. Pharm Acta Helve, 1999,73(5) :227-229.
  • 6Fleming GF, Schilsky RL, Schumn LP, et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction [J]. Ann Ocol.2003,14(7) :1142-1147.
  • 7Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24 h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer [J].Anticancer Drugs, 2002,13(5) : 497-503.
  • 8Pegram MD,Pauletti G,Slammon DJ,et al.Her-2/neu as a predictive marker of response to breast cancer therapy[J].Breast Cancer Res Treat,1998,52:65.
  • 9Bonadonna G, Zambetti M, Valagussa P.Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results[J].JAMA,1995,273(7):542.
  • 10Mamounas EP. Present state and future prospects: a review of cooperative groups adjuvant and neoadjuvant trials in breast cancer[J].Clin Breast Cancer,2001,2 Suppl 1:S20-30.

共引文献31

同被引文献5

引证文献1

二级引证文献3

中国肿瘤临床
2005年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部